Lbp Am Sa Reduces Stock Position in Johnson & Johnson (NYSE:JNJ)

LBP AM SA reduced its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 48.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 205,951 shares of the company's stock after selling 190,832 shares during the period. LBP AM SA's holdings in Johnson & Johnson were worth $34,155,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of JNJ. Vanguard Group Inc. increased its stake in shares of Johnson & Johnson by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company's stock valued at $33,666,460,000 after buying an additional 1,772,706 shares during the period. Geode Capital Management LLC boosted its holdings in Johnson & Johnson by 2.8% in the fourth quarter. Geode Capital Management LLC now owns 57,667,920 shares of the company's stock valued at $8,321,881,000 after acquiring an additional 1,561,036 shares in the last quarter. Northern Trust Corp increased its position in Johnson & Johnson by 12.3% during the 4th quarter. Northern Trust Corp now owns 30,813,175 shares of the company's stock valued at $4,456,201,000 after purchasing an additional 3,363,235 shares during the period. Norges Bank bought a new position in Johnson & Johnson in the 4th quarter worth $4,390,037,000. Finally, Wellington Management Group LLP lifted its position in shares of Johnson & Johnson by 1.8% in the 4th quarter. Wellington Management Group LLP now owns 24,356,572 shares of the company's stock worth $3,522,447,000 after purchasing an additional 431,205 shares during the period. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Down 0.5%

Shares of JNJ traded down $0.82 during trading hours on Friday, hitting $156.87. The company had a trading volume of 7,866,488 shares, compared to its average volume of 8,066,975. The stock has a market capitalization of $377.44 billion, a price-to-earnings ratio of 17.45, a P/E/G ratio of 2.15 and a beta of 0.41. The firm has a fifty day moving average price of $153.73 and a 200-day moving average price of $154.35. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The business had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. On average, equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 3.31%. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date was Tuesday, May 27th. Johnson & Johnson's dividend payout ratio (DPR) is currently 57.84%.

Analyst Ratings Changes

JNJ has been the topic of several research analyst reports. Raymond James Financial reduced their price target on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research report on Monday, April 14th. Morgan Stanley reaffirmed an "underperform" rating on shares of Johnson & Johnson in a research report on Thursday. Leerink Partnrs lowered Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Finally, Benchmark raised Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Eleven investment analysts have rated the stock with a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $171.00.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.